ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868

Also written as “TQB2868 Injection” and “TQB2868 injection”.

In Sino Biopharmaceutical’s pipeline, 抗PD-1/TGF-β双功能融合蛋白. Its studies are mostly in Pancreatic Neoplasms · Uterine Cervical Neoplasms, led by Sino Biopharmaceutical.

Drug pageAnti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868: every studyAll 7 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 3, 20254 company-led studies, 2 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical42 open or runningphase 3since Sep 3, 2025Jan 19, 2022Nov 2026phase 2 · NCT06767813
  • Named in Sino Biopharmaceutical’s own pipeline as TQB2868, phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 19, 2022First study: phase 1 study in Advanced Malignant TumorFirst studyNCT05198505 · 280 enrolled · China
  2. Aug 8, 2023Phase 2 study in Uterine Cervical NeoplasmsNCT05998941 · China
  3. Jan 6, 2025Phase 2 study in Pancreatic NeoplasmsNCT06767813 · 80 planned · China
  4. Sep 3, 2025Phase 3 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT07165951 · 566 planned · China

Ahead

  1. Nov 2026Primary completion: phase 2 study in Pancreatic NeoplasmsNCT06767813
  2. May 2028Primary completion: phase 3 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT07165951

TargetBeta

“抗PD-1/TGF-β双功能融合蛋白”the company's pipeline, read by Claude · source
“A bifunctional fusion protein directed against both the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279) and transforming growth factor beta (TGF-beta; TGFb), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890ruleIncytephase 33

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07165951Metastatic Pancreatic Ductal Adenocarcinoma · China3RecruitingMay 2028566
NCT06767813Pancreatic Neoplasms · China2RecruitingNov 202680
NCT05998941Uterine Cervical Neoplasms · China2WithdrawnFeb 20250
NCT05198505Advanced Malignant Tumor · China1UNKNOWNJun 2023280

How it is read

Names in the registry

  • “TQB2868 Injection”, 2 entries
  • “TQB2868 injection”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.